Showing 16 of 16 recruiting trials for “Acute myelomonocytic leukemia”
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
👨⚕️ Leland Metheny, MD, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center📍 1 site📅 Started Feb 2025View details ↗
Oral-ATO for TP53-mutated Myeloid Malignancies
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
👨⚕️ Alexandra M Stevens, Pediatric Early Phase Clinical Trial Network📍 18 sites📅 Started Feb 2025View details ↗
RecruitingNCT06111612 ↗
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
👨⚕️ Xianmin Song, MD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Jan 2024View details ↗
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
👨⚕️ John Pimanda, Professor, University of New South Wales📍 5 sites📅 Started Dec 2022View details ↗
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Mar 2022View details ↗
Study to Evaluate the Safety and Tolerability of EP0042
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Combining Active and Passive DNA Hypomethylation
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →